Tiziana Life Sciences Chief Medical Officer Dr. Matthew Davis joins Natalie Stoberman from the Proactive newsroom to share how the company is planning to file an Investigational New Drug Application for Intranasal Foralumab as a treatment of Alzheimer's Disease.
Dr. Davis says there are no FDA approved treatments for Alzheimer’s disease specific to neuroinflammation. He adds that the goal is to study three months' administration of intranasal foralumab in Alzheimer’s disease patients to see if neuroinflammatory activated microglia will return to the baseline homeostatic state.
The IND also includes seeking $3 million in non-dilutive funding from a prestigious Alzheimer’s foundation to support the Phase 2a trial.